| Gene symbol | CSF2 | Synonyms | CSF, GMCSF | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q31.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | colony stimulating factor 2 | ||||
| GTO ID | GTC1648 |
| Trial ID | NCT02923778 |
| Disease | Leiomyosarcoma | Liposarcoma | Sarcoma |
| Altered gene | GMCSF |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Talimogene Laherparepvec|Imlygic|T-VEC|JS1 34.5-hGMCSF 47- pA- |
| Co-treatment | Radiation Therapy |
| Phase | Phase2 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma |
| Year | 2016 |
| Country | Canada|United States |
| Company sponsor | National Cancer Institute (NCI) |
| Other ID(s) | NCI-2016-01461|MC1678|10056|UM1CA186686 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||